Celestino Sardu

List of Publications by Year
in descending order

106 papers	5,072 citations	70961 41 h-index	110170 64 g-index
117 all docs	117 docs citations	117 times ranked	6602 citing authors

#	Article	IF	Citations
1	Does poor glycaemic control affect the immunogenicity of the <scp>COVIDâ€19</scp> vaccination in patients with type <scp>2</scp> diabetes: The <scp>CAVEAT</scp> study. Diabetes, Obesity and Metabolism, 2022, 24, 160-165.	2.2	75
2	Sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts. Metabolism: Clinical and Experimental, 2022, 127, 154936.	1.5	37
3	Dysregulated Epicardial Adipose Tissue as a Risk Factor and Potential Therapeutic Target of Heart Failure with Preserved Ejection Fraction in Diabetes. Biomolecules, 2022, 12, 176.	1.8	20
4	Glycation of ryanodine receptor in circulating lymphocytes predicts the response to cardiac resynchronization therapy. Journal of Heart and Lung Transplantation, 2022, 41, 438-441.	0.3	19
5	An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors. International Journal of Molecular Sciences, 2022, 23, 3651.	1.8	67
6	Effect of Hyperglycemia on COVID-19 Outcomes: Vaccination Efficacy, Disease Severity, and Molecular Mechanisms. Journal of Clinical Medicine, 2022, 11, 1564.	1.0	13
7	MRI in Pregnancy and Precision Medicine: A Review from Literature. Journal of Personalized Medicine, 2022, 12, 9.	1.1	28
8	Glycaemic control is associated with SARS-CoV-2 breakthrough infections in vaccinated patients with type 2 diabetes. Nature Communications, 2022, 13, 2318.	5.8	33
9	Cardiac Hypertrophy: from Pathophysiological Mechanisms to Heart Failure Development. Reviews in Cardiovascular Medicine, 2022, 23, 165.	0.5	3
10	Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. Cardiovascular Diabetology, 2022, 21, 77.	2.7	76
11	SGLT2-inhibitors reduce the cardiac autonomic neuropathy dysfunction and vaso-vagal syncope recurrence in patients with type 2 diabetes mellitus: the SCAN study. Metabolism: Clinical and Experimental, 2022, 137, 155243.	1.5	25
12	Angiotensin receptor/Neprilysin inhibitor effects in CRTd non-responders: From epigenetic to clinical beside. Pharmacological Research, 2022, 182, 106303.	3.1	12
13	Pre-Menopausal Breast Fat Density Might Predict MACE During 10 Years of Follow-Up. JACC: Cardiovascular Imaging, 2021, 14, 426-438.	2.3	34
14	Microbiota thrombus colonization may influence athero-thrombosis in hyperglycemic patients with ST segment elevation myocardialinfarction (STEMI). Marianella study. Diabetes Research and Clinical Practice, 2021, 173, 108670.	1.1	19
15	Evidence for human diabetic cardiomyopathy. Acta Diabetologica, 2021, 58, 983-988.	1.2	11
16	Atherosclerotic Plaque Fissuration and Clinical Outcomes in Pre-Diabetics vs. Normoglycemics Patients Affected by Asymptomatic Significant Carotid Artery Stenosis at 2 Years of Follow-Up: Role of microRNAs Modulation: The ATIMIR Study. Biomedicines, 2021, 9, 401.	1.4	19
17	Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte. Cardiovascular Diabetology, 2021, 20, 99.	2.7	67
18	MicroRNAs modulation and clinical outcomes at 1 year of follow-up in obese patients with pre-diabetes treated with metformin vs. placebo. Acta Diabetologica, 2021, 58, 1381-1393.	1.2	14

#	Article	IF	Citations
19	SARS-COV-2 colonizes coronary thrombus and impairs heart microcirculation bed in asymptomatic SARS-CoV-2 positive subjects with acute myocardial infarction. Critical Care, 2021, 25, 217.	2.5	35
20	Impact of Admission Hyperglycemia on Heart Failure Events and Mortality in Patients With Takotsubo Syndrome at Long-term Follow-up: Data From HIGH-GLUCOTAKO Investigators. Diabetes Care, 2021, 44, 2158-2161.	4.3	35
21	Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease. Cardiovascular Diabetology, 2021, 20, 145.	2.7	91
22	Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2345-2353.	1.1	40
23	Functional Role of miR-155 in the Pathogenesis of Diabetes Mellitus and Its Complications. Non-coding RNA, 2021, 7, 39.	1.3	35
24	Metformin Therapy Effects on the Expression of Sodium-Glucose Cotransporter 2, Leptin, and SIRT6 Levels in Pericoronary Fat Excised from Pre-Diabetic Patients with Acute Myocardial Infarction. Biomedicines, 2021, 9, 904.	1.4	30
25	Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence. Diabetes Research and Clinical Practice, 2021, 178, 108959.	1.1	42
26	Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function. Biomedicines, 2021, 9, 1356.	1.4	45
27	Lack of effect on in-hospital mortality of drugs used during COVID-19 pandemic: Findings of the retrospective multicenter COVOCA study. PLoS ONE, 2021, 16, e0256903.	1.1	8
28	Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment. Molecular Metabolism, 2021, 54, 101337.	3.0	56
29	Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease. Reviews in Cardiovascular Medicine, 2021, 22, 755.	0.5	45
30	Response to Comment on Paolisso et al. Impact of Admission Hyperglycemia on Heart Failure Events and Mortality in Patients With Takotsubo Syndrome at Long-term Follow-up: Data From HIGH-GLUCOTAKO Investigators. Diabetes Care 2021;44:2158â€“2161. Diabetes Care, 2021, 44, e201-e202.	4.3	1
31	Continuous flow left ventricular assist devices and cardiac resynchronization: Friends or foe?. International Journal of Cardiology, 2021, 344, 138-139.	0.8	0
32	Adiponectin Related Vascular and Cardiac Benefits in Obesity: Is There a Role for an Epigenetically Regulated Mechanism?. Frontiers in Cardiovascular Medicine, 2021, 8, 768026.	1.1	11
33	Effects of Sodium-Glucose Transporter 2 Inhibitors (SGLT2-I) in Patients With Ischemic Heart Disease (IHD) Treated by Coronary Artery Bypass Grafting via MiECC: Inflammatory Burden, and Clinical Outcomes at 5 Years of Follow-Up. Frontiers in Pharmacology, 2021, 12, 777083.	1.6	31
34	Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence. Biomolecules, 2021, 11, 1834.	1.8	47
35	MicroRNAâ€33 and SIRT1 influence the coronary thrombus burden in hyperglycemic STEMI patients. Journal of Cellular Physiology, 2020, 235, 1438-1452.	2.0	57
36	Cardiosomal microRNAs Are Essential in Post-Infarction Myofibroblast Phenoconversion. International Journal of Molecular Sciences, 2020, 21, 201.	1.8	62

#	Article	IF	Citations
37	Cardiac resynchronization therapy and its effects in patients with type 2 DIAbetes mellitus OPTimized in automatic vs. echo guided approach. Data from the DIA-OPTA investigators. Cardiovascular Diabetology, 2020, 19, 202.	2.7	9
38	Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence. Archives of Cardiovascular Diseases, 2020, 113, 642-651.	0.7	9
39	Aspirin in a diabetic retinopathy setting: Insights from NO BLIND study. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1806-1812.	1.1	2
40	Implications of AB0 blood group in hypertensive patients with covid-19. BMC Cardiovascular Disorders, 2020, 20, 373.	0.7	46
41	DNA methylation profiling of CD04+/CD08+ T cells reveals pathogenic mechanisms in increasing hyperglycemia: PIRAMIDE pilot study. Annals of Medicine and Surgery, 2020, 60, 218-226.	0.5	17
42	miR-98 Regulates TMPRSS2 Expression in Human Endothelial Cells: Key Implications for COVID-19. Biomedicines, 2020, 8, 462.	1.4	103
43	Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control?. Diabetes Care, 2020, 43, 1408-1415.	4.3	341
44	Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence. Journal of Clinical Medicine, 2020, 9, 1417.	1.0	411
45	Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19. Cardiovascular Diabetology, 2020, 19, 76.	2.7	75
46	Could Antiâ€Hypertensive Drug Therapy Affect the Clinical Prognosis of Hypertensive Patients With COVIDâ€19 Infection? Data From Centers of Southern Italy. Journal of the American Heart Association, 2020, 9, e016948.	1.6	69
47	Hyperglycaemia on admission to hospital and COVID-19. Diabetologia, 2020, 63, 2486-2487.	2.9	72
48	Modulation of SERCA in Patients with Persistent Atrial Fibrillation Treated by Epicardial Thoracoscopic Ablation: The CAMAF Study. Journal of Clinical Medicine, 2020, 9, 544.	1.0	19
49	Cardiomyocyteâ€derived exosomal microRNAâ€92a mediates postâ€ischemic myofibroblast activation both in vitro and ex vivo. ESC Heart Failure, 2020, 7, 285-289.	1.4	55
50	Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients. Diabetes and Metabolism, 2020, 46, 403-405.	1.4	105
51	Impact of chronic liver disease upon admission on COVID-19 in-hospital mortality: Findings from COVOCA study. PLoS ONE, 2020, 15, e0243700.	1.1	36
52	Inflammatory Related Cardiovascular Diseases: From Molecular Mechanisms to Therapeutic Targets. Current Pharmaceutical Design, 2020, 26, 2565-2573.	0.9	22
53	Relationship between albuminuric CKD and diabetic retinopathy in a real-world setting of type 2 diabetes: Findings from No blind study. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 923-930.	1.1	33
54	The dating of thrombus organization in cases of pulmonary embolism: an autopsy study. BMC Cardiovascular Disorders, 2019, 19, 250.	0.7	30

#	Article	IF	Citations
55	Metformin lactic acidosis: Should we still be afraid?. Diabetes Research and Clinical Practice, 2019, 157, 107879.	1.1	30
56	Pericoronary fat inflammation and Major Adverse Cardiac Events (MACE) in prediabetic patients with acute myocardial infarction: effects of metformin. Cardiovascular Diabetology, 2019, 18, 126.	2.7	56
57	Thrombus Aspiration inÂHyperglycemic Patients With High Inflammation Levels in Coronary Thrombus. Journal of the American College of Cardiology, 2019, 73, 530-531.	1.2	23
58	Diabetes Mellitus and Its Cardiovascular Complications: New Insights into an Old Disease. Journal of Diabetes Research, 2019, 2019, 1-2.	1.0	27
59	Genetic and epigenetic-sensitive regulatory network in immune response: a putative link between HLA-G and diabetes. Expert Review of Endocrinology and Metabolism, 2019, 14, 233-241.	1.2	10
60	Cardiac syncope recurrence in type 2 diabetes mellitus patients vs. normoglycemics patients: The CARVAS study. Diabetes Research and Clinical Practice, 2019, 151, 152-162.	1.1	14
61	Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study. Cardiovascular Diabetology, 2019, 18, 24.	2.7	78
62	High HDL cholesterol: A risk factor for diabetic retinopathy? Findings from NO BLIND study. Diabetes Research and Clinical Practice, 2019, 150, 236-244.	1.1	35
63	Editorial: Diabetes and Heart Failure: Pathogenesis and Novel Therapeutic Approaches. Frontiers in Physiology, 2019, 10, 253.	1.3	4
64	Abdominal Fat SIRT6 Expression and Its Relationship with Inflammatory and Metabolic Pathways in Pre-Diabetic Overweight Patients. International Journal of Molecular Sciences, 2019, 20, 1153.	1.8	27
65	Effects of Metformin Therapy on Coronary Endothelial Dysfunction in Patients With Prediabetes With Stable Angina and Nonobstructive Coronary Artery Stenosis: The CODYCE Multicenter Prospective Study. Diabetes Care, 2019, 42, 1946-1955.	4.3	105
66	How to Induce Arrhythmias by Atrial and Ventricular Programmed Stimulation?. , 2019, , 7-18.		0
67	Why is chronic obstructive pulmonary disease linked to atrial fibrillation? A systematic overview of the underlying mechanisms. International Journal of Cardiology, 2019, 276, 149-151.	0.8	19
68	Prior beta blocker treatment decreases leukocyte responsiveness to injury. JCI Insight, 2019, 4, .	2.3	20
69	Nonâ€ST‐elevation myocardial infarction outcomes in patients with type 2 diabetes with nonâ€obstructive coronary artery stenosis: Effects of incretin treatment. Diabetes, Obesity and Metabolism, 2018, 20, 723-729.	2.2	63
70	Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: clinical outcomes at 1-year follow-up. Cardiovascular Diabetology, 2018, 17, 152.	2.7	48
71	Letter by Sardu et al Regarding Article, â€œPersistent Long-Term Structural, Functional, and Metabolic Changes After Stress-Induced (Takotsubo) Cardiomyopathyâ€. Circulation, 2018, 138, 954-955.	1.6	2
72	Applicability of telemedicine in the screening of diabetic retinopathy (DR): The first multicentre study in Italy. The No Blind Study. Diabetes/Metabolism Research and Reviews, 2018, 35, e3113.	1.7	55

#	Article	IF	Citations
73	ELectrophysiological mechanisms underlying the Inhibitory CArdiac syncope without asystolic significant pause. Medicine (United States), 2018, 97, e11757.	0.4	6
74	Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate. Cardiovascular Diabetology, 2018, 17, 137.	2.7	45
75	Inflammatory Cytokines and SIRT1 Levels in Subcutaneous Abdominal Fat: Relationship With Cardiac Performance in Overweight Pre-diabetics Patients. Frontiers in Physiology, 2018, 9, 1030.	1.3	41
76	Stretch, Injury and Inflammation Markers Evaluation to Predict Clinical Outcomes After Implantable Cardioverter Defibrillator Therapy in Heart Failure Patients With Metabolic Syndrome. Frontiers in Physiology, 2018, 9, 758.	1.3	35
77	Effects of incretin treatment on cardiovascular outcomes in diabetic STEMI-patients with culprit obstructive and multivessel non obstructive-coronary-stenosis. Diabetology and Metabolic Syndrome, 2018, 10, 1.	1.2	102
78	Quit smoking to outsmart atherogenesis: Molecular mechanisms underlying clinical evidence. Atherosclerosis, 2017, 257, 242-245.	0.4	42
79	Effects of Alpha Lipoic Acid on Multiple Cytokines and Biomarkers and Recurrence of Atrial Fibrillation Within 1 Year of Catheter Ablation. American Journal of Cardiology, 2017, 119, 1382-1386.	0.7	58
80	123I-MIBG Scintigraphy in the Subacute State of Takotsubo Cardiomyopathy. JACC: Cardiovascular Imaging, 2017, 10, 93-94.	2.3	9
81	Cardiac electrophysiological alterations and clinical response in cardiac resynchronization therapy with a defibrillator treated patients affected by metabolic syndrome. Medicine (United States), 2017, 96, e6558.	0.4	34
82	Multipolar pacing by cardiac resynchronization therapy with a defibrillators treatment in type 2 diabetes mellitus failing heart patients: impact on responders rate, and clinical outcomes. Cardiovascular Diabetology, 2017, 16, 75.	2.7	30
83	Serum adiponectin levels are associated with worse cognitive function in postmenopausal women. PLoS ONE, 2017, 12, e0186205.	1.1	21
84	Cardiac Biomarkers Predict 1-Year Mortality in Elderly Patients Undergoing Hip Fracture Surgery. Orthopedics, 2017, 40, e417-e424.	0.5	25
85	Awaking Blood Pressure Surge and Progression to Microalbuminuria in Type 2 Normotensive Diabetic Patients. Journal of Diabetes Research, 2016, 2016, 1-6.	1.0	7
86	Cardiac Resynchronization Therapy Outcomes in Type 2 Diabetic Patients: Role of MicroRNA Changes. Journal of Diabetes Research, 2016, 2016, 1-8.	1.0	28
87	Telemonitoring in heart failure patients treated by cardiac resynchronisation therapy with defibrillator (CRT-D): the TELECART Study. International Journal of Clinical Practice, 2016, 70, 569-576.	0.8	69
88	Author's reply. Journal of Cardiology, 2016, 67, 573.	0.8	1
89	Letter by Sardu et al Regarding Article, â€œCirculating MicroRNA-30d Is Associated With Response to Cardiac Resynchronization Therapy in Heart Failure and Regulates Cardiomyocyte Apoptosis: A Translational Pilot Studyâ€• Circulation, 2016, 133, e388-e388.	1.6	6
90	Authorâ€™s reply. Journal of Cardiology, 2016, 68, 89-90.	0.8	1

#	Article	IF	Citations
91	Effects of Î±-lipoic acid therapy on sympathetic heart innervation in patients with previous experience of transient takotsubo cardiomyopathy. Journal of Cardiology, 2016, 67, 153-161.	0.8	55
92	microRNA expression changes after atrial fibrillation catheter ablation. Pharmacogenomics, 2015, 16, 1863-1877.	0.6	46
93	Autonomic dysfunction is associated with brief episodes of atrial fibrillation in type 2 diabetes. Journal of Diabetes and Its Complications, 2015, 29, 88-92.	1.2	71
94	Sirtuin 6 Expression and Inflammatory Activity in Diabetic Atherosclerotic Plaques: Effects of Incretin Treatment. Diabetes, 2015, 64, 1395-1406.	0.3	156
95	Calcium release channel RyR2 regulates insulin release and glucose homeostasis. Journal of Clinical Investigation, 2015, 125, 1968-1978.	3.9	178
96	Functional role of miRNA in cardiac resynchronization therapy. Pharmacogenomics, 2014, 15, 1159-1168.	0.6	55
97	Metabolic syndrome is associated with a poor outcome in patients affected by outflow tract premature ventricular contractions treated by catheter ablation. BMC Cardiovascular Disorders, 2014, 14, 176.	0.7	52
98	Impact of Diabetes Mellitus on the Clinical Response to Cardiac Resynchronization Therapy in Elderly People. Journal of Cardiovascular Translational Research, 2014, 7, 362-368.	1.1	52
99	Peri-procedural tight glycemic control during early percutaneous coronary intervention up-regulates endothelial progenitor cell level and differentiation during acute ST-elevation myocardial infarction: Effects on myocardial salvage. International Journal of Cardiology, 2013, 168, 3954-3962.	0.8	62
100	Brief Episodes of Silent Atrial Fibrillation Predict Clinical Vascular Brain Disease in TypeÂ2 Diabetic Patients. Journal of the American College of Cardiology, 2013, 62, 525-530.	1.2	82
101	Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. nonâ€responders. European Journal of Heart Failure, 2013, 15, 1277-1288.	2.9	143
102	Implantable cardioverter defibrillator to prevent sudden cardiac death in a patient with systemic sclerosis: A clinical case. Journal of Cardiology Cases, 2012, 5, e166-e170.	0.2	2
103	Innate Immune Activity in Plaque of Patients with Untreated and<scp>l</scp>-Thyroxine-Treated Subclinical Hypothyroidism. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1015-1020.	1.8	61
104	Use of a non-specific immunomodulation therapy as a therapeutic vasculogenesis strategy in no-option critical limb ischemia patients. Atherosclerosis, 2010, 208, 473-479.	0.4	22
105	NT-proBNP, IGF-I and survival in patients with chronic heart failure. Growth Hormone and IGF Research, 2007, 17, 288-296.	0.5	51
106	Effects of volume loading on strain rate and tissue Doppler velocity imaging in patients with idiopathic dilated cardiomyopathy. Journal of Cardiovascular Medicine, 2006, 7, 852-858.	0.6	18